Gait Training Through a Novel Over-ground Wearable Robotic System in People with Pyramidal Hemisyndromes (GAITGO)

October 2, 2024 updated by: IRCCS San Raffaele Roma

Longitudinal Pilot Study on the Feasibility of Integrating Gait Training Through a Novel Over-ground Wearable Robotic System to Traditional Rehabilitation in People with Pyramidal Hemisyndromes.

Over-ground exoskeletons for gait rehabilitation are studied enough in people suffering spinal cord injury, and its clinical use is escalating in the industrialized countries. Nevertheless, studies on gait rehabilitation through exoskeletons in subjects with Pyramidal Hemisyndrome (PH) are recognized by GRADE as Low Quality of evidence.

This interventional longitudinal pilot study is aimed to investigate the feasibility, clinical effects, and compliance (from the experienced therapists (Indego Specialists)' point of view) of using an over-ground wearable robotic system (Indego) for gait rehabilitation of people with PH in the clinical practice.

Two substudies will be conducted with the following aims: to explore changes in the gait pattern and muscle activity following Indego-assisted gait rehabilitation through the kinematic gait analysis (in subjects able to walk) associated with surface electromyography (sEMG) of 4 muscle groups of the lower limbs; to identify prognostic factors for walking recovery, investigating also the effect of the treatment on functional connectivity through the electroencephalographic (EEG) analysis.

In order to satisfy the study aims, 30 subjects with PH and walking impairment will be recruited and assessed both clinically and instrumentally (in case of substudies) at the beginning (T0) and the end (T1) of the treatment period.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

The primary objective of this interventional longitudinal pilot study is to investigate the feasibility of using an over-ground wearable robotic system (Indego) for gait rehabilitation of people with PH associated with the traditional rehabilitation.

Secondary objectives of the study are:

  • To explore the clinical effects of the treatment;
  • To evaluate the feasibility of implementing this system in clinical practice from experienced therapists (Indego Specialists)' point of view.

Two Sub-Studies (SS) will be conducted with the following aims:

  1. Kinematic gait analysis (in subjects able to walk) associated with surface electromyography (sEMG) of 4 muscle groups of the lower limbs in order to evaluate changes in the gait pattern and muscle activity following gait rehabilitation through an over-ground wearable exoskeleton system;
  2. Electroencephalographic (EEG) analysis in order to: identify prognostic factors for walking recovery; investigate the effect of the treatment on functional connectivity.

30 subjects with PH and walking impairment who meet the research project inclusion and exclusion criteria will be recruited for this study. Patients will be evaluated at T0 and at T1. Demographic (gender, date of birth, height, weight, education, dominant side, work activity, presence of the social network, presence of architectural barriers at home) and clinical data (comorbidity, drug therapy, blood pressure, the cardiac frequency at rest, date of last acute event, number of previous neurological events, location of acute events) of all participants will be recorded at T0. In the case of Sub-Studies, 10 patients (able to walk fo 4 meters without aids but with supervision) for SS1 and 5 patients for SS2 following the first-ever monofocal cerebrovascular acute event will be recruited. These subjects will be assessed both clinically and instrumentally (SS1: through the gait analysis and sEMG; SS2: through the EEG) at T0 and T1.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Roma, Italy, 00163
        • IRCCS San Raffaele Pisana

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Single or multiple unilateral Cerebral Stroke
  • Mild / moderate Traumatic Brain Injury
  • Brain Tumor Benign

  • Possibility to keep the upright position for at least 1 minute with good cardiovascular compensation and:

    • With double support and supervision;
    • With double support without supervision;
    • With single support and supervision;
    • With single support without supervision;
    • With assistance not exceeding 50%;
    • With supervision only.

Exclusion Criteria:

  • Severe cognitive impairment or behavioral dysfunction such as not to understand or participate in the whole execution
  • Refusal or impossibility to provide informed consent

  • Impossibility to wear the robot:

    • for serious functional limitations in the coxo-femoral joints and knees;
    • marked hyper tone with sudden spasms in flexion;
    • Modified Ashworth Scale > 3;
    • weight over 113 Kg;
    • height less than 155 cm or higher than 195 cm;
    • hip width greater than 46 cm.
  • Sever cardio-respiratory co-morbidities.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Indego-Assisted Gait Rehabilitation

Every session of Indego-assisted gait rehabilitation will last 30 minutes, excluding preparation times (dressing, measurements, and adaptation of the brace to the anthropological measures of the various patients). The Indego program will be set based on the patient's ambulatory abilities, assessed by the Functional Ambulation Classification (FAC):

  • subjects unable to walk or high-.assistance needed (FAC = 0-2): Motion + program;
  • Subjects able to walk with mid/mini assistance or with supervision only (FAC = 3-5): Therapy + program.
  • During the treatment, the program change from Motion + to Therapy + is allowed based on the experts' opinion.
Device: Indego Therapy
Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in 6 Minute Walk Test (6MWT)
Time Frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
The 6MWT measures the distance a subject covers during an indoor gait on a flat, hard surface in 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The minimal detectable change in distance for people with sub-acute stroke is 60.98 meters. The 6MWT is a patient self-paced walk test and assesses the level of functional capacity. Patients are allowed to stop and rest during the test. However, the timer does not stop. If the patient is unable to complete the test, the time is stopped at that moment. The missing time and the reason of the stop are recorded.
Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in 10 Meter Walk Test (10MWT)
Time Frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
This test will assess the patient's speed during gait. Patients will be asked to walk at their preferred maximum and safe speed. Patients will be positioned 1 meter before the start line and instructed to walk 10 meters, and pass the end line approximately 1 meter after. The distance before and after the course is meant to minimize the effect of acceleration and deceleration. Time will be measured using a stopwatch and recorded to the one-hundredth of a second (ex: 2.15 s). The test will be recorded 3 times, with adequate rests between them. The average of the 3 times should be recorded.
Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in Timed Up And Go (TUG)
Time Frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
The TUG is a test used to assess mobility, balance, and walking in people with balance impairments. The subject must stand up from a chair (which should not be leaned against a wall), walk a distance of 3 meters, turn around, walk back to the chair and sit down - all performed as quickly and as safely as possible. Time will be measured using a chronometer.
Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in Modified Ashworth Scale (MAS)
Time Frame: Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
The MAS is a 6 point ordinal scale used for grading hypertonia in individuals with neurological diagnoses. A score of 0 on the scale indicates no increase in tone while a score of 4 indicates rigidity. Tone is scored by passively moving the individual's limb and assessing the amount of resistance to movement felt by the examiner.
Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
Change in Trunk Control Test (TCT)
Time Frame: Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
The TCT assesses the motor impairment in stroke patients and it's correlated with eventual walking ability. Testing is done with the patient lying on a bed: (1) roll to weak side. (2) roll to strong side. (3) balance in sitting position on the edge of the bed with the feet off the ground for at least 30. (4) sit up from lying down. Total score: 0-100.
Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
Change in Functional Ambulation Classification (FAC)
Time Frame: Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
FAC is a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device.
Session 1 (treatment onset, T1), and Session 15+2 (end of treatment, T2).
Change in Barthel Index (BI)
Time Frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
The BI is a measure of Activity of Daily Living (ADL), which shows the degree of independence of a patient from any assistance. Each performance item is rated on this scale with a given number of points assigned to each level or ranking. It uses ten variables describing ADL and mobility. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital.
Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in Walking Handicap Scale (WHS)
Time Frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
WHS is a classification of 6 functional walking categories, considered as a participation category of the ICF because of its 3 items referred to community ambulation. The score ranges from 1 to 6, and do higher values represent a better outcome.
Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Change in Motricity Index (MI)
Time Frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).

The MI aims to evaluate lower limb motor impairment after stroke, administrated on both sides.

Items to assess the lower limbs are 3, scoring from 0 to 33 each: (1) ankle dorsiflexion with foot in a plantar flexed position (2) knee extension with the foot unsupported and the knee at 90° (3) hip flexion with the hip at 90° moving the knee as close as possible to the chin. (no movement: 0, palpable flicker but no movement: 9, movement but not against gravity :14, movement against gravity movement against gravity: 19, movement against resistance: 25, normal:33)

1 leg score for each side = SUM (points for the 3 leg tests) + 1 Interpretation: minimum score: 0; maximum score:100
Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gait Analysis (GA)
Time Frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Kinematic and kinetic gait parameters will be calculated from data acquired with a motion capture system (SMART-DX; BTSBioengneering, Italy). DAVIS HILL protocol will be applied. Each subject (able to walk) will perform at least 3 trials, each consisting of 3 meters self-paced speed walk under condition with shoes and orthoses/aids if needed.
Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).
Electroencephalography (EEG)
Time Frame: Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).

EEG data will be recorded (250 Hz sampling rate) with a 128-electrode system placed on the scalp (10-10 augmented system) (Geodesic; ElectricalGeodesic, Inc .; Oregon, USA). The EEG signals, recorded during the entire test, will be involved in offline processing processes that will include a pre-processing for the removal of noisy channels (bad channel), filtering in the 0.3-45 Hz band, and removal of artifacts by means of the technique of Independent Component Analysis (ICA). Subsequently, the signals will be filtered by MATLAB in the bands of interest alpha and beta and segmented into epochs.

Time-frequency algorithms will allow to characterize brain activity in response to motor tasks by calculating the event-related desynchronization/synchronization index (ERD / ERS).

Acquisitions will be carried out in: relaxed sitting position (Open Eyes / Closed Eyes) for 2 min; standing position (Open Eyes) for 1 min, and during ankles flexion-extension (hip and knee in 90°).
Session 1 (Baseline-day1, T1), and Session 15 (end of treatment-day 35, T2).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

IRCCS San Raffaele Roma

Investigators

  • Principal Investigator: Sanaz Pournajaf, Dr., IRCCS San Raffaele Pisana
  • Study Chair: Marco Franceschini, Prof., IRCCS San Raffaele Pisana

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Estimated)

May 21, 2025

Study Completion (Estimated)

December 30, 2025

Study Registration Dates

First Submitted

September 7, 2020

First Submitted That Met QC Criteria

September 16, 2020

First Posted (Actual)

September 23, 2020

Study Record Updates

Last Update Posted (Actual)

October 4, 2024

Last Update Submitted That Met QC Criteria

October 2, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RP 20/13

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Indego Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe